title: Chronic nephrotoxicity in psoriatic patients treated with low-dose cyclosporine.
abstract: Chronic nephrotoxicity is a major complication in high-dose cyclosporine treatment. We examined the glomerular filtration rate, renal plasma flow, and kidney biopsies of 15 psoriatic patients treated with low-dose cyclosporine (< or = 5 mg/kg/d) for 30 months (25 to 35 months) 1 month after drug withdrawal. The mean (95% confidence interval) age of the patients in the study was 44 years (38 to 50 years). Their serum creatinine levels pretreatment and at the time of the study were 0.94 mg/dL (0.85 to 1.0 mg/dL) and 1.2 mg/dL (1.1 to 1.3 mg/dL). Seven patients had a decreased glomerular filtration rate and four of them also had a reduced renal plasma flow, below the 2.5 percentile of normal. Four patients had moderate tubulointerstitial scarring and arteriolopathy, while the remaining patients had mild structural abnormalities. The severity of acute nephrotoxicity during treatment and chronic structural injury were highly correlated (r = 0.81; P < 0.0003). Recurrent episodes of severe acute nephrotoxicity (defined as reversible increase of serum creatinine > 90% of baseline value) was a marker for moderate chronic nephrotoxicity. No correlation was found between chronic structural injury and patient age, sex, pretreatment creatinine level, blood pressure (pretreatment or during treatment), cyclosporine dose and treatment duration, and cyclosporine blood levels. In seven patients continued on cyclosporine for another 12 months (10 to 14 months), repeat studies showed no interval changes. Despite 40 months (30 to 51 months) of treatment, all but one of these seven patients (with previous hypertension and atherosclerotic vascular disease) had mild functional and structural abnormalities. None had any severe acute nephrotoxicity at any time.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, Toronto Hospital, Ontario, Canada.
authors.forename: Y
authors.initials: Y
authors.lastname: Pei
authors.forename: J W
authors.initials: JW
authors.lastname: Scholey
authors.forename: A
authors.initials: A
authors.lastname: Katz
authors.forename: R
authors.initials: R
authors.lastname: Schachter
authors.forename: G F
authors.initials: GF
authors.lastname: Murphy
authors.forename: D
authors.initials: D
authors.lastname: Cattran
mesh_terms: D000328:Adult; D001706:Biopsy; D001794:Blood Pressure; D002908:Chronic Disease; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D007674:Kidney Diseases / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy*; D017595:Renal Plasma Flow; D012307:Risk Factors
chemical_list: D016572:Cyclosporine; D003404:Creatinine